Low-Burden TP53 mutations occur in chronic phase of myeloproliferative neoplasms regardless of hydroxyurea administration, disease type and JAK2 status
By clicking “Accept Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Settings